Universidade Luterana do Brasil-ULBRA, Canoas/RS/Brazil.
BMC Infect Dis. 2009 Dec 31;9:216. doi: 10.1186/1471-2334-9-216.
Tuberculosis is one of the most prominent health problems in the world, causing 1.75 million deaths each year. Rapid clinical diagnosis is important in patients who have co-morbidities such as Human Immunodeficiency Virus (HIV) infection. Direct microscopy has low sensitivity and culture takes 3 to 6 weeks 123. Therefore, new tools for TB diagnosis are necessary, especially in health settings with a high prevalence of HIV/TB co-infection.
In a public reference TB/HIV hospital in Brazil, we compared the cost-effectiveness of diagnostic strategies for diagnosis of pulmonary TB: Acid fast bacilli smear microscopy by Ziehl-Neelsen staining (AFB smear) plus culture and AFB smear plus colorimetric test (PCR dot-blot).From May 2003 to May 2004, sputum was collected consecutively from PTB suspects attending the Parthenon Reference Hospital. Sputum samples were examined by AFB smear, culture, and PCR dot-blot. The gold standard was a positive culture combined with the definition of clinical PTB. Cost analysis included health services and patient costs.
The AFB smear plus PCR dot-blot require the lowest laboratory investment for equipment (US$ 20,000). The total screening costs are 3.8 times for AFB smear plus culture versus for AFB smear plus PCR dot blot costs (US$ 5,635,760 versus US$ 1,498, 660). Costs per correctly diagnosed case were US$ 50,773 and US$ 13,749 for AFB smear plus culture and AFB smear plus PCR dot-blot, respectively. AFB smear plus PCR dot-blot was more cost-effective than AFB smear plus culture, when the cost of treating all correctly diagnosed cases was considered. The cost of returning patients, which are not treated due to a negative result, to the health service, was higher in AFB smear plus culture than for AFB smear plus PCR dot-blot, US$ 374,778,045 and US$ 110,849,055, respectively.
AFB smear associated with PCR dot-blot associated has the potential to be a cost-effective tool in the fight against PTB for patients attended in the TB/HIV reference hospital.
结核病是世界上最突出的健康问题之一,每年导致 175 万人死亡。在合并有人类免疫缺陷病毒(HIV)感染等合并症的患者中,快速临床诊断非常重要。直接显微镜检查的灵敏度较低,培养需要 3 至 6 周时间。因此,需要新的结核病诊断工具,特别是在 HIV/TB 合并感染率较高的卫生环境中。
在巴西的一家公共参考结核病/艾滋病医院中,我们比较了诊断肺结核的诊断策略的成本效益:抗酸杆菌染色显微镜检查(Ziehl-Neelsen 染色)加培养和抗酸杆菌染色加比色试验(PCR 斑点印迹)。2003 年 5 月至 2004 年 5 月,连续收集了在 Parthenon 参考医院就诊的疑似肺结核患者的痰液。痰液样本通过抗酸杆菌染色、培养和 PCR 斑点印迹进行检查。金标准是结合临床肺结核的定义的阳性培养。成本分析包括卫生服务和患者成本。
抗酸杆菌染色加 PCR 斑点印迹需要最低的实验室设备投资(20,000 美元)。与抗酸杆菌染色加培养相比,总筛查成本高 3.8 倍(56,357,600 美元对 14,986,660 美元)。抗酸杆菌染色加培养和抗酸杆菌染色加 PCR 斑点印迹的每例正确诊断病例的成本分别为 50,773 美元和 13,749 美元。考虑到所有正确诊断病例的治疗成本,抗酸杆菌染色加 PCR 斑点印迹比抗酸杆菌染色加培养更具成本效益。由于结果为阴性而将未接受治疗的患者送回卫生服务机构的成本在抗酸杆菌染色加培养中高于抗酸杆菌染色加 PCR 斑点印迹,分别为 374,778,045 美元和 110,849,055 美元。
抗酸杆菌染色联合 PCR 斑点印迹可能成为治疗结核病/艾滋病参考医院就诊患者结核病的一种具有成本效益的工具。